Technical Analysis for APLS - Apellis Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade B 18.9 -4.06% -0.80
APLS closed down 4.06 percent on Friday, March 22, 2019, on 3.12 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Down
See historical APLS trend table...

Date Alert Name Type % Chg
Mar 22 MACD Bearish Signal Line Cross Bearish 0.00%
Mar 22 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Mar 22 Volume Surge Other 0.00%
Mar 22 Wide Bands Range Expansion 0.00%
Mar 22 Overbought Stochastic Strength 0.00%
Mar 21 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -4.06%
Mar 21 NR7 Range Contraction -4.06%
Mar 21 Inside Day Range Contraction -4.06%
Mar 21 Wide Bands Range Expansion -4.06%
Mar 21 Overbought Stochastic Strength -4.06%

Older signals for APLS ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company's lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade. The Company is developing APL-2 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) by subcutaneous injection, which is an injection into the tissue under the skin. It is developing APL-2 for the treatment of geographic atrophy (GA) and intermediate age-related macular degeneration (AMD) by intravitreal injection, which is an injection into the eye. The Company is developing APL-1 for the treatment of chronic obstructive pulmonary disease (COPD) by inhaled administration.
Medicine Biopharmaceutical Clinical Medicine Organ Systems Macular Degeneration Chronic Obstructive Pulmonary Disease Autoimmune And Inflammatory Diseases Paroxysmal Nocturnal Hemoglobinuria Acquired Hemolytic Anemia Treatment Of Chronic Obstructive Pulmonary Disease Complement System Pnh
Is APLS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 32.0
52 Week Low 11.45
Average Volume 382,253
200-Day Moving Average 16.9482
50-Day Moving Average 15.6024
20-Day Moving Average 18.153
10-Day Moving Average 19.23
Average True Range 1.0329
ADX 22.38
+DI 18.12
-DI 15.3766
Chandelier Exit (Long, 3 ATRs ) 16.9313
Chandelier Exit (Short, 3 ATRs ) 16.1387
Upper Bollinger Band 21.7215
Lower Bollinger Band 14.5845
Percent B (%b) 0.6
BandWidth 39.315816
MACD Line 1.1964
MACD Signal Line 1.2462
MACD Histogram -0.0499
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 20.45
Resistance 3 (R3) 20.56 20.17 20.19
Resistance 2 (R2) 20.17 19.77 20.11 20.10
Resistance 1 (R1) 19.53 19.53 19.34 19.42 20.02
Pivot Point 19.14 19.14 19.04 19.08 19.14
Support 1 (S1) 18.50 18.74 18.31 18.39 17.78
Support 2 (S2) 18.11 18.50 18.05 17.70
Support 3 (S3) 17.47 18.11 17.61
Support 4 (S4) 17.36